Iris Löw-Friedrich

Iris Löw-Friedrich currently works at Celosia Therapeutics Pty Ltd., as Chairman, Satellos Bioscience, Inc., as Director from 2025, PhRMA Foundation, as Director from 2019, Financière de Tubize SA, as Director from 2025, Swedish Orphan Biovitrum AB, as Director from 2025, Fresenius SE & Co. KGaA, as Independent Member-Supervisory Board from 2016, BioNTech SE, as Member-Supervisory Board from 2026, and Johann Wolfgang Goethe-Universität Frankfurt am Main, as Professor from 2000.
Dr. Löw-Friedrich also formerly worked at Zogenix, Inc., as President & Chief Executive Officer, Transcelerate Biopharma, Inc., as Chairman from 2015 to 2017, Evotec SE, as Chairman-Supervisory Board from 2021 to 2026, Heidelberg Pharma AG, as Director-Supervisory Board from 2007 to 2010, Hoechst AG, as Vice President-Clinical Development from 1992 to 2000, BASF SE, as Vice President-Global Projects from 2000 to 2001, UCB Pharma GmbH, as Head-Research & Development from 2001 to 2009, Aventis Pharma AG, as Head-Global Clinical Management & VP, Hoechst Marion Roussel, Inc., as Vice President-Clinical Development, BASF Pharma, as Vice President-Global Projects from 2000 to 2001, UCB SA, as Chief Medical Officer & Executive Vice President from 2008 to 2024, and Frankfurt University Medical School, as Staff Physician-Internal Medicine from 1985 to 1992.
Dr. Löw-Friedrich received her doctorate degree in 1985 from Johann Wolfgang Goethe-Universität Frankfurt am Main.